Mesa Laboratories Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Mesa Laboratories is gedaald met een gemiddeld jaarlijks percentage van -93.5%, terwijl de winst van de Life Sciences -industrie jaarlijks groeide met 11.7%. De inkomsten zijn groeide met een gemiddeld percentage van 16.2% per jaar.

Belangrijke informatie

-93.5%

Groei van de winst

-93.3%

Groei van de winst per aandeel

Life Sciences Groei van de industrie	21.5%
Inkomstengroei	16.2%
Rendement op eigen vermogen	-152.2%
Nettomarge	-107.6%
Laatste winstupdate	30 Sep 2024

Recente prestatie-updates uit het verleden

Recent updates

We Think Mesa Laboratories (NASDAQ:MLAB) Can Stay On Top Of Its Debt

Oct 17

A Piece Of The Puzzle Missing From Mesa Laboratories, Inc.'s (NASDAQ:MLAB) 27% Share Price Climb

Jul 29

Is Now An Opportune Moment To Examine Mesa Laboratories, Inc. (NASDAQ:MLAB)?

May 03

Is Mesa Laboratories (NASDAQ:MLAB) Using Too Much Debt?

Mar 15

Mesa Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Feb 08

Investor Optimism Abounds Mesa Laboratories, Inc. (NASDAQ:MLAB) But Growth Is Lacking

May 31

A Look At The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Apr 12

Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?

Mar 13

Estimating The Fair Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Dec 20

Mesa Laboratories declares $0.16 dividend

Oct 03

Mesa Laboratories: Softening Bottom Line Fundamentals, Fairly Priced

Sep 09

Are Investors Undervaluing Mesa Laboratories, Inc. (NASDAQ:MLAB) By 41%?

Sep 06

Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?

Aug 08

Mesa Laboratories GAAP EPS of -$0.27 misses by $0.27, revenue of $50.45M misses by $1.72M

Aug 04

Mesa Laboratories declares $0.16 dividend

Jul 07

Opbrengsten en kosten

Hoe Mesa Laboratories geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGS:MLAB Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 24	228	-246	112	19
30 Jun 24	224	-250	111	19
31 Mar 24	216	-254	111	19
31 Dec 23	213	1	110	19
30 Sep 23	214	-1	106	20
30 Jun 23	219	2	107	20
31 Mar 23	219	1	110	20
31 Dec 22	222	-1	112	21
30 Sep 22	223	-4	114	21
30 Jun 22	200	-2	103	19
31 Mar 22	184	2	89	16
31 Dec 21	163	8	76	13
30 Sep 21	143	5	68	11
30 Jun 21	139	4	66	11
31 Mar 21	134	3	64	10
31 Dec 20	130	-2	60	10
30 Sep 20	128	-2	58	9
30 Jun 20	121	-2	54	8
31 Mar 20	118	2	51	6
31 Dec 19	110	5	46	5
30 Sep 19	105	10	40	4
30 Jun 19	104	8	40	4
31 Mar 19	103	7	40	4
31 Dec 18	104	10	37	3
30 Sep 18	101	-2	36	3
30 Jun 18	99	0	35	3
31 Mar 18	96	-3	35	4
31 Dec 17	94	-4	34	4
30 Sep 17	94	11	34	4
30 Jun 17	95	11	34	4
31 Mar 17	94	11	33	4
31 Dec 16	94	12	33	4
30 Sep 16	90	11	33	4
30 Jun 16	88	10	31	4
31 Mar 16	85	11	29	4
31 Dec 15	78	9	28	4
30 Sep 15	76	9	27	4
30 Jun 15	73	10	25	4
31 Mar 15	71	10	24	3
31 Dec 14	68	11	23	3
30 Sep 14	64	10	21	3
30 Jun 14	58	9	20	2
31 Mar 14	53	9	18	2
31 Dec 13	50	8	16	2

Kwaliteitswinsten: MLAB is momenteel verliesgevend.

Groeiende winstmarge: MLAB is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: MLAB is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 93.5% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van MLAB over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: MLAB is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Life Sciences industrie ( -4.7% ).

Rendement op eigen vermogen

Hoge ROE: MLAB heeft een negatief Return on Equity ( -152.15% ), omdat het momenteel verliesgevend is.

Mesa Laboratories Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Second quarter 2025 earnings: EPS exceeds analyst expectations

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Mesa Laboratories, Inc. Reports Impairment of Goodwill and Long-Lived Assets for the Fourth Quarter Ended March 31, 2024

Mesa Laboratories, Inc. to Report Q4, 2024 Results on May 24, 2024

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Mesa Laboratories, Inc. to Report Q3, 2024 Results on Feb 05, 2024

Recent updates

Second quarter 2025 earnings: EPS exceeds analyst expectations

CEO, President & Director recently sold US$572k worth of stock

CEO, President & Director notifies of intention to sell stock

We Think Mesa Laboratories (NASDAQ:MLAB) Can Stay On Top Of Its Debt

First quarter dividend of US$0.16 announced

Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on December 16, 2024

Insider notifies of intention to sell stock

Price target increased by 10% to US$130

A Piece Of The Puzzle Missing From Mesa Laboratories, Inc.'s (NASDAQ:MLAB) 27% Share Price Climb

Fourth quarter dividend of US$0.16 announced

Mesa Laboratories, Inc., Annual General Meeting, Aug 30, 2024

Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on September 16, 2024

Mesa Laboratories, Inc. announced delayed annual 10-K filing

Mesa Laboratories, Inc. announced delayed annual 10-K filing

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Mesa Laboratories, Inc. Reports Impairment of Goodwill and Long-Lived Assets for the Fourth Quarter Ended March 31, 2024

Upcoming dividend of US$0.16 per share

Is Now An Opportune Moment To Examine Mesa Laboratories, Inc. (NASDAQ:MLAB)?

Third quarter dividend of US$0.16 announced

Mesa Laboratories, Inc. Declares Regular Quarterly Dividend, Payable on June 14, 2024

Mesa Laboratories, Inc. to Report Q4, 2024 Results on May 24, 2024

Is Mesa Laboratories (NASDAQ:MLAB) Using Too Much Debt?

Consensus EPS estimates upgraded to US$0.055 loss

Upcoming dividend of US$0.16 per share

Mesa Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

New minor risk - Earnings quality

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Mesa Laboratories, Inc. Appoints Mark Capone to Its Board of Directors

Mesa Laboratories, Inc. Declares Regular Quarterly Dividend, Payable on March 15, 2024

Insider notifies of intention to sell stock

Mesa Laboratories, Inc. to Report Q3, 2024 Results on Feb 05, 2024

Is Mesa Laboratories, Inc. (NASDAQ:MLAB) Trading At A 43% Discount?

Upcoming dividend of US$0.16 per share at 0.7% yield

Price target decreased by 17% to US$115

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Mesa Laboratories, Inc. (NasdaqGS:MLAB) entered into a definitive agreement to acquire Beijing GKE Science & Technology Co. LTD for €5 million.

Mesa Laboratories, Inc. (NasdaqGS:MLAB) acquired Sterilization indicators business of GKE-GmbH and SAL GmbH from Gke-GmbH for €80 million.

Price target decreased by 8.9% to US$139

Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on December 15, 2023

Is Mesa Laboratories (NASDAQ:MLAB) A Risky Investment?

Mesa Laboratories, Inc. to Report Q2, 2024 Results on Nov 06, 2023

CEO, President & Director notifies of intention to sell stock

Upcoming dividend of US$0.16 per share at 0.5% yield

Estimating The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

First quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Shareholder dilution

Mesa Laboratories, Inc., Annual General Meeting, Aug 25, 2023

We Think Mesa Laboratories (NASDAQ:MLAB) Is Taking Some Risk With Its Debt

Now 20% undervalued after recent price drop

Mesa Laboratories, Inc. to Report Q1, 2024 Results on Aug 03, 2023

CEO, President & Director exercised options and sold US$166k worth of stock

Consensus EPS estimates increase by 14%

Now 21% undervalued after recent price drop

Investor Optimism Abounds Mesa Laboratories, Inc. (NASDAQ:MLAB) But Growth Is Lacking

Price target decreased by 11% to US$178

Full year 2023 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of US$0.16 per share at 0.4% yield

Mesa Laboratories, Inc. Announces John B. Schmieder, Member of the Board of Directors, Chair of the Nominating and Governance Committee, and Member of the Audit Committee Decide Not to Stand for Re-Election

A Look At The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

VP, CFO & Chief Accounting Officer notifies of intention to sell stock

Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?

VP, CFO & Chief Accounting Officer notifies of intention to sell stock

Upcoming dividend of US$0.16 per share at 0.4% yield

VP, CFO & Chief Accounting Officer exercised options and sold US$132k worth of stock

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

VP, CFO & Chief Accounting Officer exercised options and sold US$293k worth of stock

Independent Director exercised options and sold US$137k worth of stock

Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on March 15, 2023

Estimating The Fair Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)